<DOC>
	<DOCNO>NCT02952586</DOCNO>
	<brief_summary>This phase 3 randomize , placebo control study evaluate safety anti-tumor activity Avelumab combination standard care chemoradiation ( SoC CRT ) versus SoC CRT alone front-line treatment patient locally advanced head neck cancer .</brief_summary>
	<brief_title>Study To Compare Avelumab In Combination With Standard Care Chemoradiotherapy ( SoC CRT ) Versus SoC CRT Definitive Treatment In Patients With Locally Advanced Squamous Cell Carcinoma Of The Head And Neck ( JAVELIN HEAD AND NECK 100 )</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Squamous Cell</mesh_term>
	<mesh_term>Head Neck Neoplasms</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<criteria>Histological diagnosis squamous cell carcinoma oral cavity , oropharynx , hypopharynx , larynx HPV negative disease , Stage III , IVa , IVb Non oropharyngeal HPV positive disease , Stage III , IVa , IVb HPV positive oropharyngeal disease T4 , N2c , N3 No prior therapy advanced stage SCCHN ; eligible definitive CRT curative intent . Available tumor sample submission willing undergo tumor biopsy : Age ≥18 year ( ≥19 Korea ; 20 year Japan Taiwan ) . ECOG Performance Status ( PS ) 0 1 ( Appendix 2 ) . Adequate bone marrow function Adequate renal function Adequate liver function Pregnancy test ( patient childbearing potential ) negative screen Prior immunotherapy anti PD 1 , anti PD L1 , anti PD L2 , anti CD137 , anti CTLA 4 antibody ( include ipilimumab ) , antibody drug specifically target T cell co stimulation immune checkpoint pathway . Major surgery 4 week prior randomization . Diagnosis malignancy within 5 year prior randomization , except superficial esophageal cancer ( TIS T1a ) fully resect endoscopy , prostate cancer ( Gleason score ≤6 ) either curatively treat deemed require treatment , ductal situ carcinoma breast complete curative treatment , adequately treat basal cell squamous cell skin cancer , carcinoma situ cervix bladder . Active autoimmune disease Any follow 6 month prior randomization : myocardial infarction , severe/unstable angina , coronary/peripheral artery bypass graft , symptomatic congestive heart failure , cerebrovascular accident , transient ischemic attack , symptomatic pulmonary embolism . Active infection require systemic therapy . Use immunosuppressive medication time randomization Prior organ transplantation include allogenic stemcell transplantation . Diagnosis prior immunodeficiency know human immunodeficiency virus ( HIV ) acquire immunodeficiency syndrome ( AIDS ) relate illness . Hepatitis B virus ( HBV ) hepatitis C virus ( HCV ) infection Vaccination within 4 week prior randomization . Current use anticipate need treatment anticancer drug . Pregnant female patient , breastfeed female patient , male patient able father child female patient childbearing potential unwilling unable use 2 highly effective method contraception outline protocol duration study least 6 month last dose cisplatin 60 day last dose avelumab/placebo ( whichever later ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
</DOC>